Previous candidate gene and genome-wide association studies have identified common genetic variants in LPA associated with the quantitative trait Lp(a), an emerging risk factor for cardiovascular disease. These associations are population-specific and many have not yet been tested for association with the clinical outcome of interest. To fill this gap in knowledge, we accessed the epidemiologic Third National Health and Nutrition Examination Surveys (NHANES III) and BioVU, the Vanderbilt University Medical Center biorepository linked to de-identified electronic health records (EHRs), including billing codes (ICD-9-CM) and clinical notes, to test population-specific Lp(a)-associated variants for an association with myocardial infarction (MI) among African Americans. We performed electronic phenotyping among African Americans in BioVU ≥40 years of age using billing codes. At total of 93 cases and 522 controls were identified in NHANES III and 265 cases and 363 controls were identified in BioVU. We tested five known Lp(a)-associated genetic variants (rs1367211, rs41271028, rs6907156, rs10945682, and rs1652507) in both NHANES III and BioVU for association with myocardial infarction. We also tested LPA rs3798220 (I4399M), previously associated with increased levels of Lp(a), MI, and coronary artery disease in European Americans, in BioVU. After meta-analysis, tests of association using logistic regression assuming an additive genetic model revealed no significant associations (p<0.05) for any of the five LPA variants previously associated with Lp(a) levels in African Americans. Also, I4399M rs3798220 was not associated with MI in African Americans (odds ratio Pacific Symposium on Biocomputing 2016 96 = 0.51; 95% confidence interval: 0.16 -1.65; p=0.26) despite strong, replicated associations with MI and coronary artery disease in European American genome-wide association studies. These data highlight the challenges in translating quantitative trait associations to clinical outcomes in diverse populations using large epidemiologic and clinic-based collections as envisioned for the Precision Medicine Initiative.
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Introduction
Labs ordered in a clinical setting provide valuable diagnostic and prognostic data at the individual patient level. In a research setting, labs can be studied to better understand the biological basis of clinical outcomes. As an example, lipid labs such as low-density lipoprotein cholesterol (LDL-C) are frequently ordered in a clinical setting to monitor the cardiovascular disease risk in patients. In turn, these labs or quantitative traits have been extensively studied in genomic research settings to identify genetic variants predictive of extreme LDL-C levels and cardiovascular disease risk [1] .
A major advantage of quantitative trait genetic studies compared with case-control outcome studies is sample size resulting in statistical power [2] . As a result, there are more or larger genome-wide association studies (GWAS) and significant findings for lipid traits compared with cardiovascular disease outcomes [1] , particularly for diverse populations. The emergence of electronic health records (EHRs) linked to biorepositories, however, provides contemporary opportunities to apply quantitative trait genetic variants to assess clinical relevance with an eye towards precision medicine.
We describe here the application of LPA genetic variants, previously associated with Lp(a) levels [3] , to assess myocardial infarction associations in both an epidemiologic and clinical African American population. Lipoprotein (a) [Lp(a)] is considered an emerging biomarker or risk factor for cardiovascular disease [4] [5] [6] whose relationship with cardiovascular disease varies across races/ethnicities. Elevated plasma Lp(a) levels have been reported to be associated with cardiovascular disease in European Americans but have not been clearly documented in African Americans [7] . Paradoxically, among participants with no previous history of cardiovascular disease, the mean Lp(a) level is two-to three-fold higher in African Americans compared with European Americans [8, 9] . The underlying cause(s) for this difference has not yet been determined.
Recent studies have identified common SNPs in LPA as strongly associated with Lp(a) levels, explaining up to 36% of the trait variance in populations of European-descent [10, 11] . In a recent epidemiologic study conducted in the Third National Health and Nutrition Examination Survey (NHANES III), we demonstrated that LPA common genetic variants were associated with Lp(a) levels in a population-specific manner [3] . LPA SNP rs3798220 (I4399M) has also been associated with cardiovascular disease [11] [12] [13] [14] and severe cardiovascular disease [15] in several European-descent populations. Thus, common genetic variants in LPA are strong predictors of both Lp(a) levels and cardiovascular disease risk in at least one population. We test here whether LPA variants associated with Lp(a) levels in African Americans are associated with myocardial infarction in African Americans ascertained from epidemiologic and clinical settings.
Methods

Study population
The study populations presented here include the epidemiologic Third National Health and Nutrition Examination Survey (NHANES III) and the clinical BioVU, Vanderbilt University Medical Center's biorepository linked to de-identified electronic health records. NHANES III is a cross-sectional survey conducted between 1988 and 1994 by the National Center for Health Statistics at the Centers for Disease Control and Prevention. NHANES ascertained noninstitutionalized Americans regardless of health status. Demographic, health, and lifestyle data were collected on NHANES participants through surveys, labs, and physical exams in the Mobile Examination Center (MEC). DNA is available on consenting phase 2 participants (ascertained between 1991 and 1994). The present study was approved by the CDC Ethics Review Board. Because the study investigators did not have access to personal identifiers, this study was considered non-human subjects research by the Vanderbilt University Internal Review Board.
BioVU operations [16] and ethical oversight [17] have been previously described. Briefly, DNA is extracted from discarded blood drawn for routine clinical care at Vanderbilt outpatient clinics in Nashville, Tennessee and surrounding areas. The DNA samples are linked to a deidentified version of the patient's EHR. The de-identified version of the EHR is referred to as the "Synthetic Derivative." The data in this study were de-identified in accordance with provisions of Title 45, Code of Federal Regulations, part 46 (45 CFR 46); therefore, this study was considered non-human subjects research by the Vanderbilt University Internal Review Board.
Phenotyping
Race/ethnicity in NHANES III is self-identified, which is concordant with global genetic ancestry for non-Hispanic whites and non-Hispanic blacks [18] . Myocardial infarction (MI) case status in NHANES III was based on data collected from a physical examination, administered by a physician, in the MEC. A continuous cardiac infarction/injury score (CIIS) was calculated based on 12 lead electrocardiogram (ECG) multiplied by 10. Those participants with a CIIS ≥ 20 were considered to have probable infarction/injury and those with a CIIS < 20 but ≥ 15 were considered to have possible infarction/injury. These thresholds correspond to an estimated specificity level of 98% and 95% [19] , respectively. Our NHANES III MI case definition included participants classified as having possible or probable infarction/injury.
Race/ethnicity in BioVU is administratively assigned, which is highly concordant with genetic ancestry for European Americans and African Americans [20, 21] . The de-identified EHR in BioVU contains both structured (International Classification of Diseases, Ninth Revision, Clinical Modification billing codes [ICD-9-CM]; current procedural terminology codes; problems lists; labs) and unstructured (clinical free text) data that are accessible for electronic phenotyping. We explored five different electronic phenotyping strategies to identify cases of MI using mentions of ICD-9-CM codes (Table 1) among African American adults ≥ 40 years of age. MI case review was performed in 2013 using the browser search function in the Synthetic Derivative user interface to find the following keywords in the patient's clinical notes: myocardial infarction, MI, infar, STEMI, and NSTEMI. If none of the keywords were found in the record, the case reviewer searched for ICD-9-CM code 410 in the record and extracted the clinic visit date associated with the ICD-9-CM code. The case reviewer then searched the remainder of the patient's records on that clinic visit date for evidence of an MI. The ECG records of all possible cases were also accessed for review. Patients were considered unconfirmed for MI if EHR review failed to identify evidence of MI in the patient's medical history. Unconfirmed cases of MI were excluded from genotyping as cases. Positive predictive values (PPVs) were calculated as the total number of confirmed cases divided by the total number of potential cases. A total of 311 MI cases were identified for genotyping in BioVU.
Controls in BioVU were defined as African American adults ≥ 40 years of age with no mention of ICD-9-CM codes of MI (410) or any other codes relating to ischemic heart disease (ICD-9-CM 411-414). A total of 5,883 potential controls were identified in BioVU. Controls were frequency matched to cases by age and sex prior to selection for genotyping.
Genotyping
Genotyping in NHANES III was performed using the Illumina GoldenGate assay (as part of a custom 384 OPA) by the Center for Inherited Disease Research (CIDR) through the National Heart Lung and Blood Institute's Resequencing and Genotyping Service, as previously described [3] . Vanderbilt Technologies for Advanced Genomics (VANTAGE) genotyped BioVU samples for six LPA SNPs (rs3798220, rs41271028, rs6907156, rs10945682, rs1652507, and rs1367211) using Sequenom. Genotyping quality control for NHANES III was performed using SAS version 9.2 and for BioVU using PLINK [22] .
Statistical methods
Tests of association in NHANES III were performed using SAS version 9.2 (SAS Institute, Cary, NC). Each LPA variant associated with Lp(a) levels in non-Hispanic blacks [3] was tested for association with MI status (dependent variable) using logistic regression assuming an additive genetic model adjusting for 1) age and sex and 2) age, sex, and ln(Lp[a]+1). Data was accessed remotely from the CDC's Research Data Center (RDC) in Hyattsville, Maryland using Analytic Data Research by Email (ANDRE) [23] . In BioVU, tests of association between MI (the dependent variable) and LPA SNPs were performed with PLINK using logistic regression assuming an additive genetic model and adjusting for age and sex (Lp[a] levels are not available in BioVU). Meta-analyses were performed with METAL using a fixed-effects inverse-variance weighted approach [24] , and results were visualized using Synthesis-View [25, 26] .
Results
As noted in the Methods section, cases of MI in NHANES III were identified using a continuous cardiac infarction/injury score applied to ECGs, an exam administered by public health professionals as part of the survey. In contrast, we used electronic phenotyping approaches to extract cases of MI from EHRs of African American patients. We used ICD-9-CM billing codes in various combinations in an attempt to achieve the largest samples size possible with acceptable PPV. As might be expected, the most stringent case definitions (Table 1 ; definitions 1 and 2) where codes for MI were required on three and two consecutive days identified the fewest number of cases at PPVs >99% after manual review. These cases of MI likely represent incident inpatient cases of MI in BioVU at the time of data extraction. Equally high in PPV but low in case count was case definition 3 where three or more ICD-9-CM codes were required. The least stringent case definitions 4 and 5 yielded the most confirmed cases (205 and 311, respectively) at acceptably high PPVs ( Table 1 ). The high PPVs observed here are consistent with other studies examining the accuracy of using ICD-9-CM codes to identify cases of acute MI [27] [28] [29] [30] . Of the 311 total cases identified in the Synthetic Derivative, only 265 passed quality control after genotyping (12 had insufficient DNA for genotyping; two were compromised samples; 14 failed genotyping). We previously tested 19 LPA SNPs for an association with Lp(a) levels in non-Hispanic blacks in NHANES III, 12 of which were associated at p < 0.0001 [3] . We tested here the same 19 LPA SNPs for an association with MI in non-Hispanic blacks from NHANES III. Despite the limitation of small sample size (n cases = 93), five LPA variants (rs1367211, rs1652507, rs6907156, rs10945682, and rs41271028) were associated with risk of MI in non-Hispanic blacks at p < 0.05 (Table 2; Figure 1) . Interestingly, four of the five alleles associated with increased risk of MI were also associated with decreased Lp(a) levels at p < 0.003.
To determine if the association of LPA variants and MI in non-Hispanic blacks from NHANES III was due to the putative causal role of increased Lp(a) levels in coronary artery disease, we adjusted for Lp(a) level (Table 2 ). This adjustment attenuated the associations for three of the five single-SNP associations with MI (p = 0.05, 0.05, and 0.07 for rs1367211, rs1652507, and rs10945682, respectively). In contrast, two LPA SNPs (rs6907156 and rs41271028) remained associated with MI at p < 0.05 after adjustment for Lp(a) levels. The first SNP, rs6907156, was originally associated with decreased Lp(a) levels (p = 0.0031) while the second, rs41271028, was not (p = 0.36). To replicate the NHANES III findings, we genotyped all five LPA SNPs from Table 2 in BioVU African American cases (n = 265) of MI and controls (n = 343). None of the five tests of association were significant at p < 0.05 (Figure 1) . We meta-analyzed NHANES III and BioVU tests of association and found two (rs10945682 and rs41271028) of the five associations had consistent directions of effect. However, none of the five LPA SNPs were associated with MI in the meta-analysis at p < 0.05.
Previous studies have suggested that rs3798220 (I4399M) is associated with higher Lp(a) levels and coronary artery disease risk [31, 32] in European-descent populations. In the present Pacific Symposium on Biocomputing 2016 study, we genotyped rs3798220 in BioVU African American MI cases and controls to determine if the association generalized to African-descent populations. In unadjusted tests of association, rs3798220 was not associated with MI in BioVU African Americans (odds ratio = 0.51; 95% CI: 0.16 -1.65; p-value = 0.26).
Discussion
Genome-wide association studies have identified thousands of common variants significantly associated with quantitative traits, and a fraction of these, in turn, are associated with risk for specific clinical outcomes [33] . The emergence of EHRs linked to biorepositories is enabling larger clinical outcome association studies, an important step in translating quantitative trait associations into precision medicine efforts. In the present study, we tested genetic variants associated with Lp(a) levels, an emerging risk factor for cardiovascular disease, for associations with MI in African Americans ascertained from epidemiologic and clinic-based collections. Overall, Lp(a)-associated genetic variants were not associated with MI in this small sample of African Americans, highlighting the challenges of translating strong genetic associations identified for quantitative traits to clinically relevant outcomes such as cardiovascular disease.
The lack of statistical associations may be due to a combination of imprecise phenotyping and small sample size. Indeed, precise phenotyping and phenotype harmonization across studies is a major challenge for genetic association studies. We used both an epidemiologic cross-sectional survey and an EHR-based biorepository to identify cases and controls of MI. Prevalent NHANES III cases were based on ECG scores (as opposed to self-report), and BioVU cases were likely a mixture of prevalent and incident cases identified using primarily billing codes. As detailed above, we deliberately applied the least stringent MI case definition to identify the largest number of cases for manual review, a strategy that identifies "silver standard" cases that can then be combined with gold standard cases to potentially boost statistical power [34] . This silver standard strategy is likely to play a major role in the Precision Medicine Initiative as it is anticipated that the one million participants will be a combination of prevalent and incident cases of various common disease drawn from epidemiologic and clinic-based collections [35] .
In the meta-analysis, we assumed that the case and control definitions were roughly equivalent. While there were a few tests of heterogeneity with p-values < 0.05 (such as LPA rs1652507 at p = 0.03), none were statistically significant when accounting for multiple tests. Despite the lack of evidence for gross differences in case-control definitions between the two collections, it is likely that subtle differences and possible case misclassification impacted statistical power. The NHANES III case-control definition has been shown to have high specificity, most likely resulting in good control classification (i.e., ruling out MI). Conversely, the BioVU case-control definition has high PPV or precision. Neither case-control definition addresses the underlying genetic and environmental heterogeneity typical of complex, common human diseases that, like misclassification of case-control status, decreases statistical power [36] .
The present study had a small sample size, which in combination with imprecise phenotyping, led to low statistical power. The small sample size available for MI cases and controls in both the epidemiologic and EHR-based collection was disappointing given that both were drawn from relatively large collections of DNA linked to demographic and health information. Although there were 2,108 African American participants with biospecimens, NHANES III had relatively few cases of MI. At the time this study was conducted, BioVU contained DNA samples linked to EHRs for ~12,000 African Americans. However, from among these patients, only 311 cases of MI were identified through billing codes and of these, 265 were available for genotyping. It is possible that additional cases could have been identified using the clinical notes and more sophisticated natural language processing techniques, but it is doubtful that a sufficient number of additional cases would have been identified for a substantial increase in power. It is widely noted that genome-wide studies in general are not conducted in diverse populations [37] , and those that are available generally have smaller sample sizes compared with their European counterparts [38] . This trend is unlikely to change with the rise in EHRs linked to biorepositories, and even concerted efforts such as the proposed Precision Medicine Initiative with one million participants [35] will be hard-pressed to muster sufficient sample sizes for clinically relevant outcomes in diverse populations.
In addition to imprecise phenotyping and low case-control counts available for study, low allele frequencies also contributed to low statistical power for specific tests of association. Overall, LPA rs3798220 is not common in African Americans, with a minor allele frequency of 2% in the present study. This minor allele frequency is similar to African Americans in third phase of the International HapMap Project as well as to European-descent cases and controls of coronary artery disease meta-analyzed by the CARDIoGRAM consortium [31] . The CARDIoGRAM consortium reported an odds ratio of 1.51, and assuming the same coded allele (C) and the same minor allele frequency (2%), we had ~17% power to detect an association with rs3798220 at p < 0.05.
Despite the numerous limitations, this study had several strengths. This study accessed both epidemiologic and clinic-based collections to identify cases and controls for MI among African Americans. Continued case-control collection for this and other clinically relevant outcomes is sorely needed to better translate genetic associations identified using quantitative traits to prevention, diagnosis, and treatment options for MI and other forms of cardiovascular disease at the bedside.
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